График акции Neuren Pharmaceuticals Limited
Расширенный график
Простой график
О компании
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. Подробнее| Цена ао | 10.33 |
|---|---|
| Выручка | 0.000495 |
| EBITDA | -0.0116 |
| Число акций ао | 0.13077 млрд |
| P/E | 5271.65 |
| P/S | 492.82 |
| P/BV | 17.62 |
| EV/EBITDA | -19.89 |
| Сайт | https://www.neurenpharma.com |
| Валюта | usd |
| Sector | Health Care |
| Industry | Biotechnology |
| Валюта отчета | aud |
| Изменение цены за день: | 0% (6.61) |
|---|---|
| Изменение цены за неделю: | -26.72% (9.02) |
| Изменение цены за месяц: | -28.77% (9.28) |
| Изменение цены за 3 месяца: | -53.61% (14.25) |
| Изменение цены за полгода: | -47.25% (12.53) |
| Изменение цены за год: | -5.97% (7.03) |
| Изменение цены за 3 года: | +319.68% (1.575) |
| Изменение цены за 5 лет: | +168.7% (2.46) |
| Изменение цены с начала года: | -37.05% (10.5) |
|
|
Недооценка
|
Эффективность
|
|||||||||||||||||||||||||||||||||||||
Дивиденды
|
Долг
|
Импульс роста
|
|||||||||||||||||||||||||||||||||||||
| Институционалы | Объем | Доля, % |
|---|---|---|
| Vanguard International Stock Index-Total Intl Stock Indx | 1480133 | 1.16 |
| Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund | 877162 | 0.69 |
| iShares Core MSCI EAFE ETF | 652944 | 0.51 |
| iShares MSCI EAFE Small Cap ETF | 436465 | 0.34 |
| Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index | 403572 | 0.32 |
| Schwab Strategic Tr-Schwab International Small Cap Equity ETF | 215442 | 0.17 |
| iShares Core MSCI Total International Stock ETF | 140892 | 0.11 |
| Vanguard International Stock Index-Pacific Stock Index | 128668 | 0.1 |
| College Retirement Equities Fund-Stock Account | 85378 | 0.07 |
| SEI Institutional International Tr-International Equity | 71485 | 0.06 |
| Руководитель | Должность | Оплата | Год рождения |
|---|---|---|---|
| Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A. | CEO, MD & Executive Director | 714.28k | |
| Ms. Lauren Frazer C.A. | CFO & Company Secretary | N/A | |
| Mr. Lawrence Glass BA (Biology) | Chief Science Officer | N/A | |
| Mr. Gerry Zhao | Vice President of Corporate Development | N/A | |
| Dr. Liza A. Squires M.D. | Chief Medical Officer | N/A |
Адрес: Australia, Camberwell, 697 Burke Road - открыть в Google картах, открыть Яндекс картах
Сайт: https://www.neurenpharma.com
Сайт: https://www.neurenpharma.com
